Cure8 research brief
This paper describes a new engineered, off-the-shelf regulatory T cell therapy (TRX103) designed to restore immune tolerance and that is already entering early clinical trials for treatment-refractory Crohn’s disease.
Patients with difficult-to-treat IBD may be interested because the approach aims to suppress inflammation without needing patient-derived cells.
Patients with treatment-refractory Crohn’s disease, clinicians treating complex IBD, and researchers in cell therapy and immune regulation.
Engineering company researchers report TRX103: an allogeneic, IL-10–expressing engineered Tr1 (type 1 regulatory) CD4+ cell product produced from pooled healthy donors and manufactured under GMP.
In lab studies TRX103 suppressed effector T cell proliferation and reduced pro-inflammatory cytokine production from monocytes, including cells from patients with Crohn’s disease. In animal xenograft models the cells trafficked to intestinal tissue and limited disease, and the product shows low allogeneic stimulatory capacity based on phenotypic assays.
TRX103 is described in this article as an investigational, off-the-shelf cell therapy being evaluated in early-phase clinical trials: a Phase 1/2a study in treatment-refractory Crohn’s disease (NCT06721962) and a Phase I study for GvHD prevention (NCT06462365).
The paper presents preclinical functional, phenotypic, and biodistribution data and frames the product for clinical development. This summary is based on the article abstract and reported preclinical data; it does not represent clinical outcomes or treatment recommendations.
For decisions about care, discuss trials or therapies with your gastroenterology team.
Findings reported are preclinical (in vitro and animal) and the article is an abstract-level summary of laboratory work; the product is under evaluation in Phase 1/2a trials. Early-phase trial registration numbers are provided; these studies assess safety and feasibility rather than proven effectiveness.
The summary is grounded in the article abstract and reported preclinical experiments.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so...
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical...
